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DOI 10.1016/j.ccr.2011.12.016SUMMARYTumorigenesis is caused by an uncontrolled cell cycle and the altered expression of many genes. Here, we
report a gene CREPT that is preferentially expressed in diverse human tumors. Overexpression of CREPT
accelerates tumor growth, whereas depletion of CREPT demonstrates a reversed effect. CREPT regulates
cyclin D1 expression by binding to its promoter, enhancing its transcription both in vivo and in vitro, and
interacting with RNA polymerase II (RNAPII). Interestingly, CREPT promotes the formation of a chromatin
loop and prevents RNAPII from reading through the 30 end termination site of the gene. Our findings reveal
a mechanism where CREPT increases cyclin D1 transcription during tumorigenesis, through enhancing
the recruitment of RNAPII to the promoter region, possibly, as well as chromatin looping.INTRODUCTION
Tumor development is highly related to uncontrolled cell growth
(Hanahan and Weinberg, 2000), a process where both onco-
genes and tumor suppressors are involved (Gordon et al.,
2005; Vogelstein and Kinzler, 2004). Oncogenes are upregulated
or mutated with gain of function, whereas tumor suppressors are
downregulated or lost in most tumors (Yamasaki and Pagano,
2004). Oncogenes encode growth factors, receptors, signal
transducers, and nuclear proteins including transcriptional
factors (Polsky and Cordon-Cardo, 2003; Zhang et al., 2005a,Significance
Many genes have been attributed to tumorigenesis; however,
tumors. In this study, we found a gene named CREPT that is hi
survival time of cancer patients. We revealed a mechanism w
scription of CYCLIN D1. CREPT prevents RNAPII from ‘‘readin
to the promoter of genes via the formation of a chromatin loo
of CREPT use ‘‘antiterminator’’ instead of ‘‘torpedo’’ model to
insights on the mechanisms of tumorigenesis.
92 Cancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc.2005b, 2005c), among these, cell-cycle-related proteins such
as cyclin D and cyclin-dependent kinase (CDK)s have been
demonstrated to play a major role in tumorigenesis (Johnson
andWalker, 1999; Osborne et al., 2004; Semczuk and Jakowicki,
2004; Sherr, 1996).
Cell-cycle-related proteins precisely regulate cell prolifera-
tion. CDK4/6 and CDK2 pair with their cyclins (cyclin D, E) to
control cell progression through G1 to S phase (Johnson and
Walker, 1999; Lee and Yang, 2003; Sherr, 1996). Cyclin D/
CDK4 or cyclin D/CDK6 complex forms in early G1 phase and
functions during the whole G1 to S phase transition (Lee andadditional unknown genes are to be characterized in human
ghly expressed in human tumors and is correlated with short
here CREPT promotes cell proliferation by enhancing tran-
g through’’ and possibly promotes the recycling of RNAPII
p. We provided evidence that tumor cells with a high level
accelerate transcription of CYCLIN D1. Our study provides
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CREPT Accelerates TumorigenesisYang, 2003), and phosphorylates the retinoblastoma protein
(RB), which activates the transcription factor E2F. The cyclin
E/CDK2 complex forms in mid to late G1 phase and is important
for S phase entry (Obaya and Sedivy, 2002). Activities of these
cyclins/CDKs can be regulated by CKIs (CDK inhibitors, such
as p15INK4b, p16INK4a, p21CIP1/WAF1, p27KIP1, and p57KIP2), which
act as tumor suppressors, at the protein level (Lee and Yang,
2003; Obaya and Sedivy, 2002). The G1/S transition and
progression in the S phase also requires the cyclin A/CDK2
complex. Furthermore, cyclin A2 and cyclin B1 form a complex
with CDK1 and function in the G2/M transition.
Several oncoproteins positively regulate cyclins and CDKs but
negatively regulate CKIs in tumor development (Felsher, 2003;
Polsky and Cordon-Cardo, 2003; Zhang et al., 2005a, 2005b,
2005c). Great efforts have been put on the identification and
characterization of these proteins (Felsher, 2003; Hunter and
Pines, 1994; Massague´, 2004). To date, different screenings
have been performed and numerous oncogenes have been
found (Dickins et al., 2005; Gordon et al., 2005); however, addi-
tional unknown genes are likely involved in tumor development
and it is important to identify and characterize novel genes that
regulate tumorigenesis (Bonetta, 2005).
In a search for genes related to tumors, we performed a data-
base homology screen using a recently isolated gene (p15rs),
which is functionally linked to p15INK4b (Liu et al., 2002) and
inhibits cell proliferation (Wu et al., 2010), and identified a
gene CREPT (cell-cycle-related and expression-elevated pro-
tein in tumor). Here, we demonstrate the role of CREPT in
tumorigenesis.
RESULTS
CREPT Is a Homolog of Rtt103 and Highly Conserved
across Species
Similarity searches of the NCBI protein database with a recently
reported protein p15RS (Liu et al., 2002) identified a gene with
no reported function. We named this gene CREPT (cell-cycle-
related and expression-elevated protein in tumor) based on our
later observation that this gene is related to the cell cycle and
highly expressed in tumors (GenBank accession numbers
DQ372938, DQ372939, DQ372940). Human (h) CREPT encodes
a protein of 326 amino acids with a high similarity to p15RS
(Figure S1A available online). CREPT contains an RPR domain
(regulation of nuclear pre-mRNA, or CID, CTD-interacting
domain) and is highly conserved across species (Figures S1B
and S1C). In yeast, the homologous gene is called Rtt103
(Scholes et al., 2001; Tong et al., 2001). A phylogenetic analysis
indicates that two genes,CREPT and p15RS, inmammals, birds,
fish, and Arabidopsis are homologs of yeast Rtt103, whereas in
nematode, fly, and frog only one homolog is predicted (Figures
S1B and S1C).
CREPT Is Highly Expressed in Human Tumor Tissues
To investigate the role of CREPT in human diseases, we
screened samples from patients with cancers using a mono-
clonal antibody we generated (Figure S1D). We found that
CREPT is more highly expressed in tumor tissues from colon
cancer patients (Figure 1A), whereas in the paired noncancer
tissues it is hardly (patients 1, 3, and 7) or weakly (patients 2,4, 5, and 6) detected (Figure 1A, top panel). High levels of CREPT
protein are in concordance with its mRNA levels in the tumor
tissues (Figure 1A, bottom panel).
Elevated expression of CREPT is not limited just to the colon
cancer, as we demonstrated that CREPT mRNA expression is
elevated in other cancers including lung, liver, breast, prostate,
stomach, uterine endometrium, and cervix cancers (Table 1).
Patient samples (eight patients for each cancer are shown in
Figure S1E) demonstrate that CREPT expression is dramatically
enhanced in all cancer tissues compared to the paired non-
cancer tissues. In many cases, we could not detect the expres-
sion of CREPT in noncancer tissues but observed high levels in
cancer tissues. In some cases, we detected relative high levels
of CREPT expression in noncancer tissues, but the levels were
always lower than those in the paired cancer sections (e.g., colon
cancer patient 1, breast cancer patient 7, liver cancer patients
2 and 6 in Figure S1E).
Immunohistochemistry (IHC) analyses with an anti-CREPT
antibody showed strong expression of CREPT in tumor regions
compared to paired nontumor regions in the same patients
(Figure 1B). The results also demonstrated that CREPT is highly
expressed in the nucleus of tumor cells (Figure 1B, enlarged
images). The nuclear localization was confirmed by overexpres-
sion of GFP-CREPT (Figure S1F) or immunostaining with an
anti-CREPT antibody along with DAPI in HeLa and HEK293T
cells (Figure S1G). Clearly, few CREPT positive staining cells
can be observed in the nontumor regions, whereas most of the
cells were negatively stained (Figure 1B).
In total, we examined 347 cases by RT-PCR and 466 cases by
IHC analyses for patients with eight different types of cancers.
Significantly elevated levels of CREPT mRNA or protein were
found in 83.3% or 86.5%, respectively, in tumor compared to
nontumor tissues from cancer patients (Table 1). Interestingly,
a survival analysis of 117 stomach cancer patients indicated
that positive CREPT staining was significantly correlated with
shorter survival time of the patients after surgery and treatment
(Figure 1C). CREPT is also highly expressed in most tumor cell
lines examined (Figure S1H).
CREPT Promotes Cell Proliferation In Vitro
Elevated expression of CREPT in tumor cells suggests a role
in cell proliferation. Since cells maintain high proliferation
ability during embryonic development, we sought to examine
the level of CREPT in different stages of the mouse embryos
and young mice. An RT-PCR and a northern analysis indicated
that CREPT was highly expressed during early stages of
mouse embryonic development (Figure S1I). CREPT expression
was observed in different normal tissues from mice after
birth but remained at low levels in adult mouse tissues (Fig-
ure S1J). An IHC analysis showed that 10 days after birth
tissues that highly expressed CREPT had correlated high levels
of cyclin D1 and Ki67, two cell proliferation markers (Fig-
ure S1K). These results suggest that CREPT plays a critical
role in cell proliferation during embryogenesis and mouse
development.
To address whether CREPT affects cell proliferation, we
stably overexpressed or depleted CREPT in MGC803 cells.
The results showed that cells overexpressing CREPT prolifer-
ated more rapidly than the mock cells (Figure 2A), whereas cellsCancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc. 93
Figure 1. CREPT Is Highly Expressed in Tumor Tissues
(A) CREPT is highly expressed in colon cancer. RT-PCR and western blotting were performed in colon cancer samples. P refers to paired nontumor tissue and T
tumor tissue from the same patient.
(B) CREPT is highly expressed in different tumor tissues. Immunohistological staining assays were performed with an anti-CREPT antibody (DAB staining, scale
bars, 100 mm).
(C) Expression of CREPT correlates with the survival time of stomach cancer patients. A tissue array analysis was done in 117 cases of patients with the survival
information. The percentage of CREPT-positive cells (%) was determined by counting five random views of each sample at 400-fold magnification.
See also Figure S1.
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(Figure 2B). Consistently, overexpression or depletion of
CREPT in HepG2 (Figure 2C) and HeLa (Figure S2A) cells led
to accelerated or inhibited cell proliferation. In addition to94 Cancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc.HepG2 and HeLa cells, which are of tumor origin, we also
observed similar results in a tetracycline induced CREPT-over-
expression system in NIH 3T3 cells (Figure S2B), which are
of fibroblast origin and expresses low endogenous CREPT
Table 1. Enhanced Expression of CREPT in Different Tumors
Assessed by RT-PCR and Immunohistochemistry
Tumor Organs
Upregulated Expressiona (%)
RT-PCR Immunohistochemistry
Lung 57.1 (8/14) 75.9 (22/29)
Liver 86.9 (186/214) 73.8 (118/160)
Breast 75.0 (21/28) 77.1 (27/35)
Prostate 100.0 (8/8) 100.0 (8/8)
Stomach 70.0 (14/20) 88.3 (128/145)
Colon 75.0 (15/20) 80.9 (55/68)
Uterus endometrium 79.0 (15/19) 79.2 (19/24)
Uterine cervix 91.7 (22/24) 89.7 (26/29)
Total 83.3 (289/347) 86.5 (403/466)
aUpregulated expression was defined as those the expression of CREPT
in tumor side is greater than that in paired nontumor side. The numbers in
parentheses refer to number of tumors showing increased expression/
total number of tumors.
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CREPT Accelerates Tumorigenesis(Figure S1I). Taken together, these results demonstrated that
CREPT functions as a positive regulator of cell proliferation in
both tumor-originated (epithelial) and nontumor-originated
(fibroblastic) cells.
CREPT Promotes Tumorigenesis In Vitro and In Vivo
Since CREPT is highly expressed in tumors and promotes cell
proliferation, we speculated that CREPT might enhance tumori-
genesis. To examine this hypothesis, we first performed a colony
formation assay in soft agar. The result showed that HepG2 cells
stably overexpressing CREPT producedmore colonies, whereas
cells depleted of CREPT yielded fewer colonies than mock cells
(Figure 2D). Similar results were observed with HeLa cells
(Figures S2C and S2D).
To investigate whether CREPT accelerates tumorigenesis
in vivo, we injected cells into nude mice and observed tumor
growth. The result showed that CREPT-overexpressing cells
generated larger tumors than control cells, whereas CREPT-
depleted cells formed smaller tumors (Figures 2E and 2F). In
addition, tumor appearance time (defined as the day when the
tumors become palpable after injection) was shortened to
6 days when CREPT was overexpressed, whereas depleting
CREPT expression delayed tumor appearance by additional
4.5 days (Figure 2G). Furthermore, we observed that tumors
originating from cells with CREPT overexpression showed higher
malignancy and much stronger proliferation ability as indicated
by HE staining (Figure S2E) and immunostaining with an anti-
PCNA antibody (stronger PCNA expression in CREPT overex-
pressed cells) (Figure S2F).
To address whether CREPT causes the transformation of
cells, we overexpressed CREPT in tetracycline inducible NIH
3T3 cells. A soft agar experiment showed that cells with over-
expressed CREPT formed colonies (Figure S2G). Conse-
quently, NIH 3T3 cells overexpressing CREPT formed tumors
in nude mice, whereas control cells had no ability to form
tumors (Figure S2H). These data suggested that CREPT
promotes tumor growth in vitro as well as cell transformation
in NIH 3T3 cells.CREPT Alters the Cell Cycle
A FACS analysis was performed to determine whether CREPT
enhances cell growth and promotes tumorigenesis via alter-
ation of the cell cycle. The size of the cell population in the
S phase is significantly increased with overexpression of
CREPT 12 hr after release from synchronization, whereas that
in the G1 phase remains at a low level at this same time point
in MGC803 cells (Figure 3A; Figure S3A). In contrast, the
reversed effect was observed when CREPT was depleted
(Figure 3B; Figure S3B). The proportion of cells in the G2/M
phase was either slightly decreased or unchanged when
CREPT was overexpressed (Figure 3A) or depleted (Figure 3B).
Similar results were observed with HeLa (Figure S3C) and
HepG2 (Figure S3D) cells. Furthermore, when CREPT was
overexpressed in NIH 3T3 cells, we also observed more cells
in the S phase (Figure 3C). By determining the length of
each phase, we found that the overexpression of CREPT short-
ened the cell cycle in HeLa cells (Figure S3E). These results
indicate that CREPT alters the cell cycle by promoting the G1
to S phase transition.
CREPT Regulates Expression of Genes Controlling the
Cell Cycle
Given that the cell cycle was altered by the overexpression or
depletion of CREPT, we addressed whether CREPT affects
the expression of cell-cycle-related genes. Since CREPT
affected the G1 to S phase transition (Figures 3A and 3B), we
focused our attention on genes for activators (CDK4/6/cyclin
D1 and CDK2/cyclin E/A), inhibitors (p15INK4b/16INK4a and
p21CIP1/WAF1/27KIP1), as well as downstream genes such as
RB, E2F1, and PCNA during cell-cycle regulation. An RT-PCR
analysis indicated that the cyclin D1, CDK6, and CDK4 mRNA
levels increased dramatically when CREPT expression was
induced by the withdrawal of tetracycline in the NIH 3T3 cells
(Figure 3D; Figure S3F). In contrast, cyclin A, p21CIP1/WAF1, and
p27KIP1 remained constant and p15INK4b, p16INK4a, and RB
decreased. Both cyclin E and CDK2 were also increased when
CREPT was overexpressed (Figure 3D; Figure S3F). Similar
results were observed when CREPT was overexpressed in
HeLa cells (Figure S3G, left two lanes) and the reverse trend
for the cell-cycle-related gene expression was observed when
CREPT was depleted by an siRNA in HeLa cells (Figure S3G,
right two lanes). Among these genes, we found that the CYCLIN
D1 gene, in particular, responded to the CREPT alteration
quickly (Figure 3D). These data suggested that CREPT regulates
expression of cell-cycle-related genes.
CREPT Enhances Gene Transcription Specifically
To examine whether changes in mRNA levels of genes that
CREPT regulated are at the transcription level, we performed
nuclear run-on experiments. The result indicated that transcrip-
tion of CDK4/6, cyclin D1, CDK2, and cyclin E was enhanced
when CREPT was overexpressed and almost completely
abolished when CREPT was depleted (Figure 4A). In contrast,
transcription of p15INK4b, p16 INK4a, and RB was blocked by
CREPT overexpression, and this inhibition was released when
CREPT was depleted. These data suggest that CREPT regulates
the expression of CDK4/6, cyclin D1, CDK2, and cyclin E at the
transcriptional level. Moreover, the regulation is gene specificCancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc. 95
Figure 2. CREPT Promotes Cell Proliferation and Tumorigenesis
(A) Overexpression of CREPT enhances cell growth. Cell lines originating from the MGC803 cell line (a stomach cancer cell line) were established with stable
overexpression of CREPT (western blot panels) and measured by an MTT assay. Endo. CREPT indicates the endogenous expression of CREPT. Error bars
represent ±SD.
(B) Depletion of CREPT suppresses cell growth. MGC803 cells were stably transfected with an siRNA targeting CREPT.
(C) CREPT accelerates cell growth in HeLa cells. Cell proliferation was examined by MTT experiments in HeLa cells with stable overexpression (pcDNA/CREPT)
or depletion (pBS/U6/CREPTi) of CREPT.
(D) CREPT promotes colony formation. One thousand cells from indicated cell lines based on HepG2 cells were seeded into soft agar. Colonies were stained with
crystal violet and counted. Bars represent ±SD from three independent experiments.
(E–G) CREPT promotes tumor growth. Six nudemicewere injected subcutaneously with 53 106 cells/mouse for each of the indicated stable cell lines. Results are
shown as isolated tumors (E), tumor weights (F), and tumor appearance times (G). si refers to siRNA.
See also Figure S2.
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not affected (Figure 4A).
To investigate how CREPT activates the transcription of tar-
geted genes, we selected the CYCLIN D1 promoter (Herber
et al., 1994) as this gene quickly responded to the elevation of
CREPT expression (see Figure 3D). Assays of the luciferase
reporter gene linked to the native CYCLIN D1 promoter (Fig-
ure S4A) showed that overexpression of CREPT enhanced the
luciferase activity, whereas depletion of CREPT decreased the
activity (Figure 4B; Figure S4B, also Figures S4C and S4D). A
nuclear run-off experiment with the CYCLIN D1 promoter-lucif-
erase reporter indicated that addition of nuclear extracts from
CREPT-overexpressing cells increased transcription in vitro,
whereas, in the presence of nuclear extracts from CREPT-
depleted cells, no transcripts were detected (Figure 4C). In
another nuclear run-off experiment using purified GST-CREPT
protein (Figure S4E) together with nuclear extracts from
HeLa cells, we observed that addition of GST-CREPT protein96 Cancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc.increased transcription in a dosage dependent manner in vitro
(Figure 4D). Taken together, these data suggest that CREPT
enhances the transcriptional activity of the CYCLIN D1 promoter
both in vivo and in vitro.
CREPT Interacts with RNAPII Physically
To reveal factors involved in transcription regulation by
CREPT, we performed an immunoprecipitation (IP) experiment
in HEK293T cells overexpressing Myc-CREPT. A mass spec-
trometry analysis identified RNAPII as an interacting protein
with Myc-CREPT (Figure 5A). The interaction of CREPT with
RNAPII occurred at the RPR domain as demonstrated by an IP
experiment with Flag-tagged CREPT (Figure 5B), which is
consistent with the observation that the RPR domain of yeast
Rtt103 interacts with RNAPII (Kim et al., 2004). Furthermore,
reciprocal IP analyses indicated that endogenous CREPT and
RNAPII interacted (Figures 5C and 5D) and purified GST-CREPT
protein pull-down RNAPII (Figure 5E), suggesting that CREPT
Figure 3. CREPT Alters the Cell Cycle and Cell-Cycle-Related Gene Expression
(A and B) Overexpression (A) and depletion (B) of CREPT in MGC803 cells alters the proportion of cells in the G1 and S phase. Cells were stained by propidium
iodide at the indicated time after release from synchronization with nocodazole (200 ng/ml) for 18 hr. Sizes of cell populations averaged from three independent
experiments with standard deviations. **p < 0.01.
(C) CREPT alters the cell cycle in a Tet-off system. A stable cell line was established for CREPT expression in NIH 3T3 cells under the control of tetracycline (Tet)
off system. Ectopical CREPT expression is regulated by the withdrawal of Tet. pTRE2 is an empty vector. Cells were synchronized by starvation for 24 hr.
(D) CREPT alters the expression of cell-cycle-related genes. A quantitative representation of the time response to changes of gene expression as a consequence
of ectopically expressed CREPT from a Tet-controlled expression system in NIH 3T3 cells. The complete withdrawal of Tet (Ectopic CREPT expression is
turned on) was considered to be time point 0 and used for calculating fold change. The results are presented as fold changes relative to controls where ectopic
CREPT is off.
See also Figure S3.
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CREPT Accelerates Tumorigenesisinteracts with RNAPII in vivo and in vitro. These results imply
that CREPT regulates the transcription of cyclin D1 via directly
interacting with RNAPII.
CREPT Promotes RNAPII Occupancy
on the CYCLIN D1 Gene
To examine whether CREPT functions with RNAPII in the regula-
tion of transcription of cyclin D1, we first addressed whether
CREPT is involved in the CYCLIN D1 promoter complex. Chro-
matin immunoprecipitation (ChIP) assays using different primers
across the CYCLIN D1 gene (Figure 6A) showed that promoter
region B of CYCLIN D1 was strongly precipitated down by an
anti-CREPT antibody and that overexpression of CREPT
enhanced the precipitation significantly, whereas depletion of
CREPT abolished precipitation (Figures 6B and 6C). Although
most of the other regions were not precipitated, region F, just
before the poly(A) cleavage site, was precipitated in the pres-
ence of overexpressed CREPT, similar to the result for promoter
region B (Figures 6B and 6C). These results suggest that CREPT
crosslinks strongly to the CYCLIN D1 promoter region, and alsoto a region related to transcription termination at the 30 end of
the gene.
Next, we analyzed the influence of CREPT on RNAPII binding
density across the CYCLIN D1 gene. A ChIP experiment indi-
cated that strong binding of RNAPII to the promoter region B
occurred in the presence of overexpressed CREPT, but only
weak binding with the depletion of CREPT (Figures 6D and 6E),
suggesting that CREPT enhances RNAPII binding to theCYCLIN
D1 promoter. However, CREPT did not affect RNAPII binding to
regions C, D, and E of the CYCLIN D1 gene, implying CREPT
does not affect transcription elongation. Intriguingly, CREPT
enhanced RNAPII binding to region F, a region before the poly(A)
site, and reduced RNAPII binding to region G after the poly(A)
site. In contract, depletion of CREPT resulted in less binding of
RNAPII in regions B and F, but increased RNAPII binding to
region G (Figures 6D and 6E). These results suggest that
CREPT stops RNAPII from moving beyond the poly(A) site.
The enhanced binding of RNAPII in both the promoter (B) and
termination (F) regions suggested that CREPT might promote
recycling of RNAPII from the terminator to the promoter region.Cancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc. 97
Figure 4. CREPT Accelerates CYCLIN D1 Tran-
scription
(A) CREPT regulates transcription of cell-cycle-related
genes. Nuclear run-on assays, showing the transcriptional
level of indicated genes in HepG2 cells where CREPT was
stably overexpressed or depleted, were performed.
(B) CREPT activates transcription of CYCLIN D1. A lucif-
erase reporter linkedwith the full-length native promoter of
the CYCLIN D1 gene was used for the luciferase assay.
Results were normalized with internal controls and pre-
sented as averages with standard deviations from three
repeats.
(C) CREPT enhances the transcriptional activity of the
CYCLIN D1 promoter. A nuclear run-off assay was per-
formedwith templates linearized from a luciferase reporter
linked with a short fragment of the native CYCLIN D1
promoter (186 bp). Nuclear extracts were from HEK293T
cells transfected with indicated plasmids for over-
expression or depletion of CREPT. Transcripts were
dotted onto membranes and detected with a labeled
probe from the luciferase reporter.
(D) CREPT activates transcription of CYCLIN D1 in vitro.
Purified GST-CREPT proteins were added to the nuclear
extract from HeLa cells and a nuclear run-off assay was
performed using the same templates as in (C).
See also Figure S4.
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mation capture (3C) experiment (Dekker et al., 2002) to test
whether CREPT promotes RNAPII to drive the CYCLIN D1
gene forming a chromatin loop (Figure 6F). For the 3C experi-
ment, we chose primers that do not crossreact and have high
specificity to observe loop formation. Indeed, a strong loop
band was observed in cells when CREPT was overexpressed
and the band was diminished when CREPT was depleted
(Figures 6G and 6H). To avoid possible random ligation during
the 3C experiment, we used DNA-protein complexes that were
precipitated down by an anti-RNAPII antibody (8WG16) and
performed the 3C experiment with and without ligation in
combination with NcoI digestion. The results showed that the
anti-RNAPII antibody precipitated down a strong cycled band
when CREPT was overexpressed (Figure 6I). These data indi-
cate that CREPT promotes loop formation to bring RNAPII
physically close to the transcription start site, implying that
CREPT may enhance RNAPII recycling from the terminator to
the promoter region during transcription of the CYCLIN D1
gene.
CREPT Regulates the Transcription of the CYCLIN D1
Gene in Tumors
We have proposed a mechanism where CREPT enhances
RNAPII binding to the CYCLIN D1 promoter and terminator
regions thereby driving theCYCLIN D1 gene to form a chromatin98 Cancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc.loop. To examine whether CREPT functions
to promote the chromatin loop formation in
tumors, we investigated 12 cases of colon
cancers. A western blot analysis showed a
correlation of expression of CREPT and cyclin
D1 in the tumor tissues where in most patients,
elevated expression of CRPET is coupled withhigh levels of cyclin D1 (Figure 7A, patients 7 and 8 being the
exceptions). The positive correlation of CREPT, cyclin D1, and
Ki67 expression was confirmed, by IHC experiments, in these
patient samples (Figure 7B), similar to that observed for several
other cancers including stomach, lung, prostate, endometrium,
liver, and breast cancers (Figure S5). Next, we performed
a ChIP assay with tumor samples from three patients (2, 4, and
12) with the results showing that CREPT binds strongly to
regions B and F of the CYCLIN D1 gene (Figure 7C). These
results are consistent with the results from cells overexpressing
CREPT (Figure 6D), with RNAPII strongly binding to regions
B and F and weakly to region G of the CYCLIN D1 gene in tumor
tissues (Figure 7D). Finally, we addressed whether the CYCLIN
D1 gene forms a chromatin loop in tumors. A 3C experiment
showed a strong band in tumor tissues (Figure 7E), suggesting
that a chromatin loop is formed in the cells of tumor tissues. All
of the data indicate that CREPT promotes chromatin looping of
theCYCLIN D1 gene in tumor cells, which results in an increased
binding of RNAPII to both the promoter and 30 end regions.
DISCUSSION
Many genes are known to be associated with tumor formation;
however, additional genes remain to be identified and charac-
terized (Gordon et al., 2005). Here, we report a gene CREPT
that is highly expressed in different tumors and is an oncogene
Figure 5. CREPT Interacts with RNAPII
(A) A mass spectrometry analysis of proteins associated
with CREPT. HEK293T cells were transfected with pCDNA
3.1/Myc or Myc-CREPT and cell lysates were immuno-
precipitated using an anti-Myc antibody. Precipitants
were analyzed by an SDS-PAGE gel and stained with
Coomassie blue. Bands were cut out and identified by
a mass spectrometry analysis.
(B) CREPT interacts with RNAP II. Schematic illustration of
CREPT and its deletions are presented on the top panel.
RPR domain and CCT (coiled coil terminus) are shown.
HEK293T cells were transfected with Myc-tagged full-
length and two deletions of CREPT. Cell lysates were
immunoprecipitated using an anti-Myc antibody and the
precipitants were detected with an anti-RNAP II antibody
(8WG16).
(C and D) Endogenous CREPT interacts with RNAP II
in vivo. IP experiments were performed with an antibody
against CREPT under the normal condition (C) and recip-
rocally with an antibody against RNAPII (8WG16) under
fixation with formaldehyde (4%) (D).
(E) CREPT interacts with RNAP II in vitro. A GST pull-down
assay was performed with purified GST or GST-CREPT
protein.
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nant cell growth and tumorigenesis. An anti-CREPT antibody
clearly defined tumor boundaries, although a few positive stain-
ing cells were observed occasionally in the paired nontumor
sections. These results suggest that CREPT could be used as
a marker to diagnose tumors.
Cell-cycle alteration is a major feature of tumorigenesis (John-
son andWalker, 1999), which occurs by shortening theG1 phase
(Hall and Peters, 1996; Hunter and Pines, 1994; Sherr, 1996). In
this study, we observed that CREPT increased the proportion of
cells in the S phase and, since no major change in the G2/M
phase cell populations was observed when CREPT was overex-
pressed, we concluded that CREPT accelerates the G1 to S
phase transition, and thus a shorter G1 phase, similar to the
effects of many other oncogenes (Massague, 2004; Sherr,
1996). Consistently, we found that CREPT enhanced the expres-
sion of cell-cycle-related genes. Among the genes functioning
during the G1 and S phase transition, we observed that the
CYCLIN D1 gene quickly responded to changes in CREPT
expression; therefore, we used CYCLIN D1 as an example to
study the molecular mechanisms by which CREPT promotes
cell proliferation.
CREPT contains an RPR domain, which is predicted to func-
tion in the 30 end processing of mRNA (Doerks et al., 2002) and
is a homolog of the yeast Rtt103 gene. Previous studies impli-
cated Rtt103 function in Ty1 transposition (Scholes et al.,
2001) and in cell viability and growth (Tong et al., 2001). The
Rtt103 protein was found in RNAPII complexes associatedCancer Cell 21,with other factors (Rat1, Pcf11) (Kim et al.,
2004). Similar to the polyadenylation factors
Rna14, Rna15, and Pcf11, Rtt103 was reported
to strongly bind near the 30 end of genes and to
help Rat1 in degrading mRNA downstream of
poly(A) site cleavage (Kim et al., 2004), support-
ing the ‘‘torpedo’’ model in the termination oftranscription (Buratowski, 2009; Connelly and Manley, 1989;
Moore and Proudfoot, 2009; Proudfoot, 1989). Previous IP
experiment and structure-based analyses indicated that Rtt103
preferred to bind to Ser2P CTD of RNAPII (Kim et al., 2004;
Lunde et al., 2010), downstream of the poly(A) site at the 30
end of genes in yeast. To our surprise, we observed that CREPT
bound not only to the region BEFORE the poly(A) site, but also to
the promoter region of the CYCLIN D1 gene. Interestingly,
CREPT promotes RNAPII binding to both the promoter and the
termination region before the poly(A) site and decreases
RNAPII binding to the region after the poly(A) site. Together
with our results from the 3C experiments, we propose that
CREPT helps RNAPII recycle from the termination site to the
promoter region of the CYCLIN D1 gene through a chromatin
loop (Figure 6F). CREPT binding to the 30 end of the gene
appears to prevent RNAPII from ‘‘reading through,’’ and allows
RNAPII to be recruited back to the promoter. The function of
CREPT in binding to the 30 end of CYCLIN D1 gene revealed in
this study supports the allosteric (antiterminator) model for
transcription termination (Luo and Bentley, 2004; Moore and
Proudfoot, 2009), a model that explains the recycling of
RNAPII from the termination to the promoter site (Mapendano
et al., 2010).
Gene looping has been observed in the regulation of gene
transcription in both yeast (O’Sullivan et al., 2004) and mamma-
lian cells (Perkins et al., 2008; Tan-Wong et al., 2008). In
this study, we observed that CREPT promotes loop formation
at CYCLIN D1. We envisioned that this loop formation might92–104, January 17, 2012 ª2012 Elsevier Inc. 99
Figure 6. CREPT Promotes RNAPII Recycling in the CYCLIN D1 Gene
(A) A graphic representation of theCYCLIND1 genomic structure. P1, P2, and P3 are predicated promoter regions. The P2 promoter has been functionally defined
as the site of initiation of transcription of theCYCLIND1 gene. E1 to E5 represent exons. Numbers indicate the nucleotides counting from the primary transcription
start site as +1. Fragments detected by PCR are shown as A to G.
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However, we could not exclude the possibility that CREPT has
independent functions at the promoter region, as an activator,
and the terminator. It is possible that CREPT may function
directly in the promoter region to enhance the initiation of tran-
scription and thereafter promote loop formation. We cannot
exclude the possibility that the loop is required for enhanced
transcription. It is possible that the loop functions as an
enhancer, as has been observed for the estrogen receptor
positive enhancer of the CYCLIN D1 gene in breast cancer
(Eeckhoute et al., 2006). In this study, we conclude that the
loop formation is coupled with transcription initiation, possibly
acting as an enhancer, as we found that CREPT associates
with RNAPII.
Yeast Rtt103 appears to only function as a factor in transcrip-
tional termination (Kim et al., 2004) as the RPR domain of Rtt103
binds to the Ser2P CTD of RNAPII in yeast (Lunde et al., 2010).
Here, we observed that CREPT binds to both the promoter
and the 30 end of the CYCLIN D1 gene. CREPT appears to help
RNAPII stop at the poly(A) site, functioning as a terminator for
the gene transcription, a role conceivable since yeast Rtt103
has been shown to function as a termination factor. However,
the role of CREPT at the 50 end of a gene, in the regulation of
the gene transcription, seems different from that of its yeast
ortholog Rtt103. A difference in the roles of CREPT appears
not only in the binding to the promoter, where yeast Rtt103
does not, but also in theway it facilitates termination.We demon-
strated that knocking down CREPT resulted in readthrough of
RNAPII past the 30 end of the CYCLIN D1 gene, whereas yeast
Rtt103 was shown to help Rat1 and Rai1 increase the degrada-
tion of nuclear mRNA after RNAPII reads through the poly(A) site
(Kim et al., 2004). Interestingly, CREPT and p15RS are both
homologs of Rtt103 in mammals. Our previous study indicated
that p15RS functions as an intrinsic inhibitor of Wnt signaling
mediated transcription (Wu et al., 2010), a function different
from the role of CREPT as an oncoprotein observed in this study.
p15RS (Wu et al., 2010) and CREPT together, therefore, may
provide more regulatory functions to mammalian cells than are
provided by Rtt103 to yeast (Kim et al., 2004).
Intriguingly, we observed that CREPT is highly expressed in
human tumors. When CREPT is depleted, tumor cells grow
slowly, an observation that echoes the role of Rtt103 in maintain-
ing yeast viability and growth (Tong et al., 2001). The role of(B and C) CREPT crosslinks to a promoter region and the pre-poly(A) cleavage site
stable overexpression or depletion of CREPT. Precipitation was performed usin
indicated primers are presented. Error bars represent ±SD from three repeats. In
Mouse IgG was used as a negative control in the precipitation experiment.
(D and E) CREPT enhances RNAPII crosslinking to the promoter and the pre-poly
CYCLIN D1 gene. ChIP analyses were performed in MGC803 cells under stable o
with indicated primers for PCR (D) and real-time PCR (E) analyses. Input indicate
was used as a negative control in the precipitation experiment. Error bars repres
(F) Diagramof the primers used in the 3C assay of the humanCYCLIND1 genomic
RNAPII. Vertical lines indicate the Nco I restriction endonuclease sites, short arro
C indicates CREPT and Pol II for RNAPII.
(G and H) CREPT promotes the formation of a chromatin loop at the CYCLIN D1
shown in (G). Region E of CYCLIN D1 is used as a loading control. Real-time PC
resent ±SD from three repeats.
(I) Specificity of the chromatin loop formation is shown by a ChIP-3C experiment.
Real-time PCR result is shown as relative fold increases based on the level of thCREPT in cell-cycle regulation is attributed to the specific regu-
lation of cell-cycle-related genes. We used CYCLIN D1 as
a model to demonstrate a mechanism where CREPT regulates
gene transcription via interacting with RNAPII at both the termi-
nation and promoter regions. Consistent with cell experiments,
we observed that cells from human tumors have a strong chro-
matin loop in the CYCLIN D1 gene. Of importance, we found
that RNAPII together with CREPT accumulate in the promoter
region (region B) and region (F) before the poly(A) site but
released from DNA after the poly(A) site (see binding in region
G) (Figure 7) in human tumors. In the absence of excess CREPT,
others have shown that RNAPII accumulates in the region after
the poly(A) site of the CYCLIN D1 gene (Eeckhoute et al., 2006)
and RNAPII release generally occurs after the poly(A) site (Lian
et al., 2008), observations that supports the torpedo model of
transcription termination (Buratowski, 2009; Connelly and Man-
ley, 1989; Moore and Proudfoot, 2009; Proudfoot, 1989). In this
study, we observed that CREPT promotes the accumulation of
RNAPII in the F region, a region just before the poly(A) site. Inter-
estingly, when CREPT was depleted it appears that RNAPII
reads through the poly(A) site, the situation that has generally
been observed by others (Eeckhoute et al., 2006; Lian et al.,
2008). Our results, therefore, describe conditions where both
the torpedo and the antiterminator models are involved in the
termination of gene transcription (Kim et al., 2004; Moore and
Proudfoot, 2009). Cells appear to use the antiterminator mecha-
nism to accelerate transcription of CYCLIN D1 when CREPT is
overexpressed in tumors and the torpedo model to maintain
a lower level of cyclin D1 expression when CREPT is low as
found in normal or slowly proliferating cells. This study illustrates
a case where a gene can use different models for transcription
termination (Buratowski, 2009).
Many questions remain concerning the function of CREPT. For
example, what causes tumor cells to express CREPT at such
high levels? How does CREPT enhance RNAPII binding to the
CYCLIN D1 promoter? Does CREPT enhance transcription
termination by mechanisms similar to other RPR domain con-
taining proteins (Kim et al., 2004)? How does CREPT specifically
regulate gene expressions at the global genome level? Do other
specific factors regulate the activity of CREPT? Answering these
questions will help our understanding of the mechanisms of cell-
cycle regulation, transcription control, and tumorigenesis. In
conclusion, we reported that CREPT is a highly conservedin theCYCLIN D1 gene. ChIP analyses were performed in MGC803 cells under
g an anti-CREPT antibody. Results from PCR (B) and real-time PCR (C) using
put indicates the PCR products from cell lysates without immunoprecipitation.
(A) cleavage site and decreases binding to the post-poly(A) cleavage site of the
verexpression or depletion of CREPT using an anti-RNAPII antibody (8WG16)
s the PCR products from cell lysates without immunoprecipitation. Mouse IgG
ent ±SD from three repeats.
region and amodel of the chromatin loop of theCYCLIND1 gene byCREPT and
ws mark the positions of primers used in the 3C assay (labeled B1-5 and F1-2).
gene. Products of amplifications with various primers with purified 3C DNA is
R analyses of the products of the 3C assay are shown in (H). Error bars rep-
PCR analyses were performed on RNAPII-containing precipitated complexes.
e control normalized to the input.
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Figure 7. CREPT Promotes Chromatin Looping of the CYCLIN D1 Gene in Tumors
(A) Correlation expression of cyclin D1, PCNA, and CREPT in colon cancers. A western blot was performed for samples from colon cancer patients. P refers to
paired nontumor tissue and T refers to tumor tissue. # refers to the patient number.
(B) CREPT, cyclin D1, and Ki67 are elevated simultaneously in human colon tumor tissues. IHC was performed with colon cancer samples and a representative
image (scale bar, 200 mm) is shown.
(C) CREPT binds to both the promoter and the 30 end region of the CYCLIN D1 gene in tumors. ChIP experiments were performed in tumor or paired nontumor
tissues from three patients (1, 3, and 7).
(D) RNAPII strongly binds to both the promoter and the 30 end region of the CYCLIN D1 gene in tumors. ChIP experiments were performed as in (C).
(E) TheCYCLIND1 gene forms stronger chromatin loops in tumors. 3C experiments were performed in the tumor and paired nontumor tissues from three patients.
See also Figure S5.
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tumor development. We reveal that the mechanism by which
CREPT enhances tumor growth is by directly regulating cyclin
D1 expression at the transcriptional level. We believe that
CREPT should be another target for tumor diagnosis and therapy
development.102 Cancer Cell 21, 92–104, January 17, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Plasmids and Antibodies
Expression plasmids for human CREPT are pEGFPN1/Flag-CREPT, pGEX/
5X-2/ GST-CREPT, pcDNA6/CREPT, pcDNA3.1/Myc-CREPT, pCMV/HA-
CREPT, and pTre2/CREPT, which were constructed in our lab. The plasmid
pBS/U6/CREPT-si was constructed according to a previous protocol (Sui
Cancer Cell
CREPT Accelerates Tumorigenesiset al., 2002). The target sequence by an siRNA (CREPT-si), GGACCTGAATTC
ACTAGAGA, is identical in human and mouse. Antibodies against Flag (M2),
RNAPII (8WG16), Cyclin D1, PCNA, Ki67, and b-actin were purchased from
Santa Cruz Biotechnology and Covance Research. An anti-CREPT antibody
(3E10) was raised in our lab (see Figure S1D).
Human Tumor Specimens and Staining
Cancer tissues were collected in the Third People’s Hospital of Qidong, Qi
Dong Tumor Hospital, Wuxi 101 Hospital, the Chinese University of Hong
Kong and the Chinese PLA General Hospital in China. Tissues were kept and
stained according to routine protocols (Rong et al., 2006). The tissue collection
procedure with informed consent was approved by the Ethic Affair Committee
of the ThirdPeople’sHopspital ofQidong, theEthic andHealthCommittee ofQi
Dong Tumor Hospital, The Ethic Committee of Wuxi 101 Hospital, the Clinical
Research Ethics Committee of the Chinese University of Hong Kong, and the
Clinical Ethic Committee of the Chinese PLA General Hospital.
Western Blot, Immunoprecipitation, PCR, and RT-PCR
Experiments were performed according to protocols in the lab (Wu et al.,
2010). CREPT cDNA was amplified using the primers: (forward) 50-TATAGG
TACCATGTCCTCCTTCTCTGAG-30 and (reverse) 50-TATACTCGAGCTAGT
CAGTTGAAAACAGGTC-30. Semiquantitative PCR products were quantified
by Imagequant software (Amersham Pharmacia Biotechnology).
Cell Culture, Transfection, and Assays from Stable Cell Lines
Cells used for cell-cycle, growth, and luciferase experiments were cultured ac-
cording to previous studies (Wu et al., 2010). Tumor formation assays were
done according to a previous study (Rong et al., 2006) following the institu-
tional guidelines and regulations on the animal health and ethics, approved
by the animal health and ethics committee in Tsinghua University. All the
experiments were performed in triplicate.
Chromatin Immunoprecipitation Assay
Cells were fixed at 37C for 10 min with 1% formaldehyde for crosslinking (Wu
et al., 2010). Sonicationwasdoneat 4C for 30 s at level 2 (UltrasonicProcessor,
Sonics) to yield fragments from 100 to 400 bps. Information of primers for PCR
amplifications can be found in the Supplemental Information). The specificity of
the primers to the different regions of the CYCLIN D1 gene was examined and
no crossreaction bands were observed. The efficiency of PCR in the chromatin
immunoprecipitation (ChIP) experiments was greater than 20% when
compared with the input. Real-time PCR was performed to quantify the data.
Nuclear Run-on and Run-off Assays
For nuclear run-on assays, nuclei prepared from the indicated cells were
incubated in 2 3 Transcription Mix, 10 3 Nucleotide Mix, and 500 mCi
[32P]-dUTP at 37C for 30min. Labeled mRNA was hybridized to cDNA probes
predotted onto membranes. For nuclear run-off assays, linearized pGL3/
cyclin D1-Luc was incubated with purified GST-CREPT and HeLa cell nuclear
extracts, or with nuclear extracts from the indicated cell lines. Transcript
products were dotted on membranes and hybridized with [32P]-CTP-labeled
Luc cDNA probe.
Chromosome Conformation Capture Assay
Chromosome conformationcapture (3C) assayswere conducted essentially as
described by Dekker et al. (2002) with some modifications (see Supplemental
Information). Real-time PCR was performed to quantify the results.
ACCESSION NUMBERS
The GenBank accession numbers for human, murine, and chicken CREPT
mRNAs are DQ372938, DQ372939, and DQ372930, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
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